Skip to content

Application of personalized plasma ctDNA detection in dynamic monitoring of recurrence after resection of colorectal cancer liver metastases.

Application of personalized plasma ctDNA detection in dynamic monitoring of recurrence after resection of colorectal cancer liver metastases.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035677
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Case series:closely follow-up after blood collection

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-70 years old for both male and female; 2) With pathologically confirmed colorectal liver metastases; 3) No matter with or without neoadjuvant therapy or conversional therapy; 4) Planned to receive that radical operation for both the primary and liver metastases (both simultaneous or staged surgery accepted); 5) ECOG = 1; 6) Written informed consent signed by patients or their legal representatives can be obtained; 7) With 4-8 ml plasma available; 8) At least 2 years follow-up data available.

Exclusion criteria

Exclusion criteria: 1) Not pathologically confirmed as malignant by colonoscopy or liver biopsy; 2) With AJCC stage of I-III; 3) Diagnosed as stage IV colorectal cancer patients with extrahepatic metastasis; 4) Not able to be radically resected; 5) Withe Blood transfusion performed within 2 weeks before surgery; 6) With any signs of severe or uncontrolled systemic disease which may significantly affect the risk / benefit balance of patients, including uncontrolled hypertension, hepatitis B, hepatitis C, and human immunodeficiency virus; 7) With a history of alcoholism or drug abuse; 8) Pregnant or lactating female patients; 9) Surgical tissue samples not available.

Design outcomes

Primary

MeasureTime frame
RFS;

Countries

China

Contacts

Public ContactJunjie Peng

Fudan University Shanghai Cancer Center

pengjj67@hotmail.com+86 18017317122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026